152 related articles for article (PubMed ID: 32256654)
1. Jiawei Xianglian Decoction (JWXLD), a Traditional Chinese Medicine (TCM), Alleviates CPT-11-Induced Diarrhea in Mice.
Lu J; Lin Z; Huang S; Shen Y; Jiang J; Lin S
Evid Based Complement Alternat Med; 2020; 2020():7901231. PubMed ID: 32256654
[TBL] [Abstract][Full Text] [Related]
2. Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide.
Melo ML; Brito GA; Soares RC; Carvalho SB; Silva JV; Soares PM; Vale ML; Souza MH; Cunha FQ; Ribeiro RA
Cancer Chemother Pharmacol; 2008 Apr; 61(5):775-84. PubMed ID: 17624531
[TBL] [Abstract][Full Text] [Related]
3. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
[TBL] [Abstract][Full Text] [Related]
4. Identification of the bioactive components of Banxia Xiexin Decoction that protect against CPT-11-induced intestinal toxicity via UPLC-based spectrum-effect relationship analyses.
Shi JW; Li ZZ; Wu JS; Jin WY; Chang XY; Sun H; Dong L; Jiang ZP; Shi Y
J Ethnopharmacol; 2021 Feb; 266():113421. PubMed ID: 33022337
[TBL] [Abstract][Full Text] [Related]
5. Traditional Chinese medicine Gegen Qinlian decoction ameliorates irinotecan chemotherapy-induced gut toxicity in mice.
Wu Y; Wang D; Yang X; Fu C; Zou L; Zhang J
Biomed Pharmacother; 2019 Jan; 109():2252-2261. PubMed ID: 30551482
[TBL] [Abstract][Full Text] [Related]
6. Insight into the mechanism of Xiao-Chai-Hu-Tang alleviates irinotecan-induced diarrhea based on regulating the gut microbiota and inhibiting Gut β-GUS.
Wang C; Teng X; Wang C; Liu B; Zhou R; Xu X; Qiu H; Fu Y; Sun R; Liang Z; Zhang R; Liu Z; Zhang L; Zhu L
Phytomedicine; 2023 Nov; 120():155040. PubMed ID: 37683587
[TBL] [Abstract][Full Text] [Related]
7. Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity.
Guan HY; Li PF; Wang XM; Yue JJ; He Y; Luo XM; Su MF; Liao SG; Shi Y
Front Pharmacol; 2017; 8():769. PubMed ID: 29163158
[TBL] [Abstract][Full Text] [Related]
8. Baicalein, a component of banxia xiexin decoction, alleviates CPT-11-induced gastrointestinal dysfunction by inhibiting ALOX15-mediated ferroptosis.
Pei J; Zou Y; Zhou W; Wang Y
Chem Biol Drug Des; 2023 Dec; 102(6):1568-1577. PubMed ID: 37735740
[TBL] [Abstract][Full Text] [Related]
9. Gegen Qinlian standard decoction alleviated irinotecan-induced diarrhea via PI3K/AKT/NF-κB axis by network pharmacology prediction and experimental validation combination.
Chen J; Li M; Chen R; Xu Z; Yang X; Gu H; Zhang L; Fu C; Zhang J; Wu Y
Chin Med; 2023 Apr; 18(1):46. PubMed ID: 37106406
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo.
Cheng KW; Tseng CH; Tzeng CC; Leu YL; Cheng TC; Wang JY; Chang JM; Lu YC; Cheng CM; Chen IJ; Cheng YA; Chen YL; Cheng TL
Pharmacol Res; 2019 Jan; 139():41-49. PubMed ID: 30391354
[TBL] [Abstract][Full Text] [Related]
11. [Effect of Shengjiang Xiexin Decoction on the Repair of Damaged Rat Intestinal Mucosa after Irinotecan Chemotherapy].
Wang J; Jia LQ; Tan HY; Pan L; Yu LL; Deng B
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Oct; 35(10):1236-43. PubMed ID: 26677677
[TBL] [Abstract][Full Text] [Related]
12. Relationship between
Bai Y; Wu HW; Ma X; Liu Y; Zhang YH
Onco Targets Ther; 2017; 10():3071-3081. PubMed ID: 28790841
[TBL] [Abstract][Full Text] [Related]
13. Darunavir alleviates irinotecan-induced intestinal toxicity in Vivo.
Zhang X; Zhang G; Ren Y; Lan T; Li D; Tian J; Jiang W
Eur J Pharmacol; 2018 Sep; 834():288-294. PubMed ID: 30053408
[TBL] [Abstract][Full Text] [Related]
14. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
Takasuna K; Hagiwara T; Watanabe K; Onose S; Yoshida S; Kumazawa E; Nagai E; Kamataki T
Cancer Chemother Pharmacol; 2006 Oct; 58(4):494-503. PubMed ID: 16437251
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
Ikuno N; Soda H; Watanabe M; Oka M
J Natl Cancer Inst; 1995 Dec; 87(24):1876-83. PubMed ID: 7494232
[TBL] [Abstract][Full Text] [Related]
18. Green tea extract prevents CPT-11-induced diarrhea by regulating the gut microbiota.
Kon R; Ikarashi N; Yamaguchi A; Teshima Y; Yamaguchi T; Miyaoka K; Fukuda M; Noguchi H; Tomimoto R; Sakai H; Kamei J; Hosoe T
Sci Rep; 2023 Apr; 13(1):6537. PubMed ID: 37085597
[TBL] [Abstract][Full Text] [Related]
19. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.
Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
Cancer Res; 1996 Aug; 56(16):3752-7. PubMed ID: 8706020
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.
Yamamoto M; Kurita A; Asahara T; Takakura A; Katono K; Iwasaki M; Ryuge S; Wada M; Onoda S; Yanaihara T; Yokoba M; Mitsufuji H; Nishii Y; Fukui T; Masuda N
Oncol Rep; 2008 Oct; 20(4):727-30. PubMed ID: 18813810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
